GlassScriptPhysician profile
Sara A Barr
NPI 1801930862
$12,207.47
in general payments reported to CMS, 2019-2025
24 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $992 · 2022: $2,384 · 2023: $3,048 · 2024: $2,981 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,354 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,354.43 |
| Education | $476.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,867.78 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,225.31 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,098.66 | 2021-2025 | |
| Janssen Biotech, INC. | $903.28 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $708.13 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $668.54 | 2022-2024 | Vtama |
| Pfizer INC. | $666.48 | 2021-2025 | |
| Incyte Corporation | $620.81 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $571.73 | 2021-2025 | Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $517.40 | 2022-2025 | Sotyktu, Yervoy |
| Novartis Pharmaceuticals Corporation | $513.68 | 2021-2025 | |
| Galderma Laboratories, L.P. | $461.66 | 2021-2025 | Epsolay, Nemluvio, Aklief |
| Lilly USA, LLC | $391.79 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $380.18 | 2022-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $223.00 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $107.46 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.03 | 2022-2023 | Targretin, Siliq, Jublia |
| Mayne Pharma Commercial LLC | $52.26 | 2023-2025 | |
| Revance Therapeutics, INC. | $40.97 | 2024-2025 | Daxxify |
| Botanix Sb INC | $37.58 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.70 | 2025 | Spevigo |
| Almirall LLC | $18.11 | 2022 | |
| Amgen INC. | $16.35 | 2025 | Otezla |
| Biofrontera INC. | $11.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.